OSR Holdings, Inc. (OSRH), a global healthcare company, reported a net loss of $27.06 million for the year ended December 31, 2025, compared to a net loss of $10.33 million for the year ended December 31, 2024. The company's net sales decreased by 18% to $2.91 million in 2025 from $3.53 million in 2024, while the cost of sales decreased by 15% to $2.31 million from $2.72 million. This resulted in a gross profit of $0.59 million in 2025, a 27% decrease from $0.81 million in the previous year, primarily due to changes in contractual arrangements with suppliers and increased product costs.
Selling, general, and administrative (SG&A) expenses increased by 51% to $18.93 million in 2025, up from $12.50 million in 2024. This increase was mainly due to higher professional service fees related to the business combination and costs associated with operating as a public company, as well as increased personnel-related expenses. Research and development (R&D) expenses also increased by 98% to $0.32 million in 2025, compared to $0.16 million in 2024, primarily related to the maintenance of a cGMP facility.
The company's other expenses increased significantly to $10.55 million in 2025 from $0.20 million in 2024, driven by $8.5 million in one-time, non-cash merger-related expenses and $4.8 million related to warrants and convertible notes issued in connection with an agreement with White Lion Capital, LLC. As of December 31, 2025, OSRH had cash and cash equivalents of $1.70 million. The company has an equity line of credit with White Lion GBM Innovation Fund, providing the right, but not the obligation, to require White Lion to purchase up to $80 million in aggregate gross purchase price of newly issued shares of the company’s common stock, subject to certain limitations and conditions.
OSR Holdings is focused on advancing its subsidiaries' product candidates and expanding its portfolio through strategic transactions. In January 2026, OSRH completed the acquisition of Woori IO Co., Ltd., a South Korea-based medical device company developing non-invasive biosensing technology for glucose monitoring. The company also entered into a binding term sheet with BCM Europe AG for an exclusive global license of the VXM01 oral cancer immunotherapy platform. Management has identified material weaknesses in its internal control over financial reporting as of December 31, 2025, relating to the completeness and accuracy of liabilities and the sufficiency of personnel within the accounting and financial reporting function.
About OSR Holdings, Inc.
OSR Holdings, Inc. is a global healthcare holding company operating through subsidiaries focused on developing innovative therapies and medical devices. Its core businesses include oral T-cell immunotherapies for cancer, design-augmented biologics for age-related degenerative diseases, and neurovascular intervention device distribution in Korea. OSR leverages scientific expertise and strategic partnerships to advance drug development and commercialization, targeting unmet medical needs with a diversified, risk-managed portfolio across major healthcare markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.